https://www.yemenhealthreport.com/article/903555236-rhythm-pharmaceuticals-announces-changes-to-board-of-directors Yemen Health Report en PressRelease 2026-04-03T13:00:00+00:00 Rhythm Pharmaceuticals Announces Changes to Board of Directors https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.yemenhealthreport.com/article/903554922-bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-03T12:30:00+00:00 Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://www.yemenhealthreport.com/article/903554873-mbx-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-03T12:00:00+00:00 MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/5499b327-bce0-4a3f-96a7-04a38b68a99f/small/mbx-logos-final-full-jpg.jpg https://www.yemenhealthreport.com/article/903555000-taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-03T12:00:00+00:00 Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/a88cd5f5-0b05-416c-a56b-e4130c10cfca/small/new-taysha-inline-fullcolor-rgb-12in-300ppi-jpg.jpg https://www.yemenhealthreport.com/article/903535955-mink-therapeutics-and-memorial-sloan-kettering-to-present-phase-ii-study-of-agent-797-combination-in-pd-1-refractory-gastroesophageal-cancer-at-aacr Yemen Health Report en PressRelease 2026-04-03T11:30:00+00:00 MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 https://ml.globenewswire.com/media/6aa8e960-515a-40d6-9894-39ca47f5c84e/small/mink-logo-loyal-blue-and-light-blue-png.png https://www.yemenhealthreport.com/article/903535988-kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-03T11:30:00+00:00 Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png https://www.yemenhealthreport.com/article/903535857-biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-03T11:00:00+00:00 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://www.yemenhealthreport.com/article/903438283-cacao-bliss-claims-evaluated-the-natural-glp-1-superfood-alternative-earth-echo-s-chocolate-drink-mix-for-weight-loss Yemen Health Report en PressRelease 2026-04-03T00:10:00+00:00 Cacao Bliss Claims Evaluated: The Natural GLP-1 Superfood Alternative, Earth Echo's Chocolate Drink Mix for Weight Loss https://zingfast.com/wp-content/uploads/2026/04/Cacao-Bliss.jpg https://www.yemenhealthreport.com/article/903419453-mesa-labs-declares-quarterly-dividend Yemen Health Report en PressRelease 2026-04-02T22:00:00+00:00 MESA LABS DECLARES QUARTERLY DIVIDEND https://ml.globenewswire.com/media/ff66b401-9246-47b9-accc-2f553d346c5c/small/mesalogo-jpg.jpg https://www.yemenhealthreport.com/article/903419573-merit-medical-systems-to-announce-first-quarter-2026-results-on-april-30-2026 Yemen Health Report en PressRelease 2026-04-02T22:00:00+00:00 Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026 https://ml.globenewswire.com/media/19958d8f-47a4-44f3-a780-247335a68768/small/merit-medical-systems-inc-logo.jpg https://www.yemenhealthreport.com/article/903419504-conavi-medical-announces-results-from-its-annual-general-meeting-of-shareholders Yemen Health Report en PressRelease 2026-04-02T21:44:30+00:00 Conavi Medical Announces Results from Its Annual General Meeting of Shareholders https://ml.globenewswire.com/media/4a28f1c0-f99d-4940-b2a7-201ab98cdaff/small/conavi-jpg.jpg https://www.yemenhealthreport.com/article/903419498-newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T21:43:42+00:00 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/f7b8b881-9461-4712-9965-707ed3bdd573/small/newamsterdam-logo-full-color-final-png.png https://www.yemenhealthreport.com/article/903418492-information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company-as-of-march-31-2026 Yemen Health Report en PressRelease 2026-04-02T20:30:00+00:00 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 https://ml-eu.globenewswire.com/media/274bd0ae-19c4-4821-85ce-7fe85ee610b5/small/logo1-jpg.jpg https://www.yemenhealthreport.com/article/903418496-information-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-mars-2026 Yemen Health Report en PressRelease 2026-04-02T20:30:00+00:00 Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026 https://ml-eu.globenewswire.com/media/274bd0ae-19c4-4821-85ce-7fe85ee610b5/small/ https://www.yemenhealthreport.com/article/903418721-olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T20:30:00+00:00 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png https://www.yemenhealthreport.com/article/903418919-regeneron-collaborates-with-trinetx-to-access-de-identified-electronic-health-records-of-300-million-patients-to-drive-research-and-product Yemen Health Report en PressRelease 2026-04-02T20:30:00+00:00 Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.yemenhealthreport.com/article/903419450-serina-therapeutics-announces-nyse-american-acceptance-of-continued-listing-compliance-plan Yemen Health Report en PressRelease 2026-04-02T20:13:00+00:00 Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan https://ml.globenewswire.com/media/7f8e4304-8465-4d4d-a7e3-ebc4eae51f29/small/yellow-burts-blue-text-1-png.png https://www.yemenhealthreport.com/article/903418718-rxsight-inc-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Yemen Health Report en PressRelease 2026-04-02T20:10:00+00:00 RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/48441335-c938-45ff-9355-ba8e331354e9/small/rxsight-globe-png.png https://www.yemenhealthreport.com/article/903418651-equillium-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T20:05:00+00:00 Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/14ce766d-e697-461f-a27c-c1ee49c0eeff/small/equillium-logo-360x180-jpg.jpg https://www.yemenhealthreport.com/article/903418710-terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T20:05:00+00:00 Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) https://ml.globenewswire.com/media/cfd0bb0d-8a9b-4de4-92ce-47e8018cf3d9/small/terns-logo-rgbs-jpg.jpg https://www.yemenhealthreport.com/article/903418769-relay-therapeutics-to-present-initial-clinical-data-on-zovegalisib-in-vascular-anomalies-at-the-international-society-for-the-study-of-vascular Yemen Health Report en PressRelease 2026-04-02T20:05:00+00:00 Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 https://ml.globenewswire.com/media/079b6db5-ce81-4a81-9cde-d97f86c569ae/small/logo-banner-small-png.png https://www.yemenhealthreport.com/article/903418814-fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T20:05:00+00:00 Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://www.yemenhealthreport.com/article/903418840-candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T20:05:00+00:00 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://www.yemenhealthreport.com/article/903418845-minerva-announces-leadership-transition Yemen Health Report en PressRelease 2026-04-02T20:05:00+00:00 Minerva Announces Leadership Transition https://ml.globenewswire.com/media/69e604cb-25b6-4235-ae9a-17c25cc158b9/small/minerva-logo.jpg https://www.yemenhealthreport.com/article/903419076-akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T20:05:00+00:00 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.yemenhealthreport.com/article/903398555-fibrobiologics-announces-closing-of-3-million-public-offering Yemen Health Report en PressRelease 2026-04-02T20:01:00+00:00 FibroBiologics Announces Closing of $3 Million Public Offering https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.yemenhealthreport.com/article/903399500-praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T20:01:00+00:00 Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.yemenhealthreport.com/article/903400112-summary-notice-of-pendency-and-proposed-settlement-of-stockholder-derivative-actions Yemen Health Report en PressRelease 2026-04-02T20:01:00+00:00 Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions https://ml.globenewswire.com/media/3a5f958d-422c-4a97-a96d-cf06f640b587/small/exicure-logo-final-full-color-072515-png.png https://www.yemenhealthreport.com/article/903400085-visory-health-se-posiciona-entre-las-principales-tarjetas-de-descuento-para-medicamentos-bajo-prescripci-n-en-estados-unidos-ofreciendo-a-millones-de Yemen Health Report en PressRelease 2026-04-02T19:40:55+00:00 Visory Health se posiciona entre las principales tarjetas de descuento para medicamentos bajo prescripción en Estados Unidos, ofreciendo a millones de personas acceso a tratamientos asequibles https://ml.globenewswire.com/media/e5a74903-3e24-4101-9d07-c377482b32ec/small/visory-health-logo-png.png https://www.yemenhealthreport.com/article/903400069-get-summer-season-ready-with-new-notorious-fitness-training-plans Yemen Health Report en PressRelease 2026-04-02T19:35:59+00:00 Get Summer-Season Ready with New Notorious Fitness Training Plans https://ml.globenewswire.com/media/485cb087-ce87-45bc-bd40-7b164d7bda7a/small/logo-ni-png.png https://www.yemenhealthreport.com/article/903400049-mediwound-reports-barda-contract-award-to-vericel-for-nexobrid-valued-at-up-to-197-million Yemen Health Report en PressRelease 2026-04-02T19:26:11+00:00 MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg https://www.yemenhealthreport.com/article/903399638-vericel-announces-barda-award-valued-at-up-to-197-million-for-procurement-and-advanced-development-of-nexobrid Yemen Health Report en PressRelease 2026-04-02T18:40:00+00:00 Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid https://ml.globenewswire.com/media/6a144258-8523-493f-8a1e-ccceec233208/small/vericel-corporation-logo.jpg https://www.yemenhealthreport.com/article/903382944-cherry-picking-science-wva-condemns-eu-tobacco-report Yemen Health Report en PressRelease 2026-04-02T16:39:14+00:00 Cherry-Picking Science: WVA Condemns EU Tobacco Report https://ml.globenewswire.com/media/23d44cef-b934-4430-a66e-f7a36a326666/medium/world-vapers-alliance.jpeg https://www.yemenhealthreport.com/article/903380596-genfit-r-sultats-financiers-annuels-2025-et-point-sur-les-activit-s-de-la-soci-t Yemen Health Report en PressRelease 2026-04-02T16:30:20+00:00 GENFIT : Résultats financiers annuels 2025 et point sur les activités de la Société   https://ml-eu.globenewswire.com/media/ZTkzMGRhNzItOGJkZS00NWRhLTllNWYtY2RmZmVhMWVlNTZiLTEwMTEyNjgtMjAyNi0wNC0wMi1mcg==/tiny/GENFIT-S-A-.png https://www.yemenhealthreport.com/article/903380643-genfit-reports-full-year-2025-financial-results-and-provides-corporate-update Yemen Health Report en PressRelease 2026-04-02T16:30:20+00:00 GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update   https://ml-eu.globenewswire.com/media/ZTkzMGRhNzItOGJkZS00NWRhLTllNWYtY2RmZmVhMWVlNTZiLTEwMTEyNjgtMjAyNi0wNC0wMi1lbg==/tiny/GENFIT-S-A-.png https://www.yemenhealthreport.com/article/903380423-medicana-health-group-marks-world-autism-awareness-day-with-a-call-for-inclusion-earlier-recognition-and-family-centered-support Yemen Health Report en PressRelease 2026-04-02T16:00:00+00:00 Medicana Health Group Marks World Autism Awareness Day with a Call for Inclusion, Earlier Recognition and Family-Centered Support  https://ml-eu.globenewswire.com/media/4552042c-da21-40b5-90e7-122b99c64bff/medium/medicana-atakoy-hospital.png https://www.yemenhealthreport.com/article/903381718-eylea-hd-aflibercept-approved-by-fda-as-first-and-only-injectable-anti-vegf-with-dosing-intervals-up-to-5-months-for-wet-age-related-macular Yemen Health Report en PressRelease 2026-04-02T16:00:00+00:00 EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.yemenhealthreport.com/article/903360628-liv-hospital-highlights-hospital-based-stem-cell-infrastructure-during-autism-awareness-month Yemen Health Report en PressRelease 2026-04-02T15:00:00+00:00 Liv Hospital Highlights Hospital-Based Stem Cell Infrastructure During Autism Awareness Month https://ml-eu.globenewswire.com/media/56455831-7774-4cd6-b91c-6ed239d89950/medium/liv-hospital-highlights-hospital-based-stem-cell-infrastruct.jpg https://www.yemenhealthreport.com/article/903363207-global-virus-network-meeting-advances-a-science-driven-agenda-for-pandemic-preparedness Yemen Health Report en PressRelease 2026-04-02T15:00:00+00:00 Global Virus Network Meeting Advances a Science-Driven Agenda for Pandemic Preparedness https://ml.globenewswire.com/media/6c1b2724-7b9b-469a-a7c3-bc0a64d716ae/small/gvn-lt-gr-gradiant-jpg.jpg https://www.yemenhealthreport.com/article/903364235-abbvie-ibd-scholarship-program-marks-15-years-applications-open-for-2026 Yemen Health Report en PressRelease 2026-04-02T15:00:00+00:00 AbbVie IBD Scholarship Program Marks 15 Years: Applications Open for 2026 https://ml.globenewswire.com/media/d853f38f-4056-484f-94ad-0d49eccd29ee/small/ccc-logo-pr-png.png https://www.yemenhealthreport.com/article/903364241-le-programme-de-bourses-d-tudes-mii-d-abbvie-f-te-ses-15-ans-les-candidatures-sont-ouvertes-pour-2026 Yemen Health Report en PressRelease 2026-04-02T15:00:00+00:00 Le programme de bourses d'études MII d’AbbVie fête ses 15 ans : les candidatures sont ouvertes pour 2026 https://ml.globenewswire.com/media/d853f38f-4056-484f-94ad-0d49eccd29ee/small/ https://www.yemenhealthreport.com/article/903360645-assisted-reproductive-technology-market-set-to-reach-6-02-billion-by-2030-marketsandmarkets Yemen Health Report en PressRelease 2026-04-02T14:30:00+00:00 Assisted Reproductive Technology Market Set to Reach $6.02 Billion by 2030 | MarketsandMarkets™ https://ml.globenewswire.com/media/afcc5182-4ae0-43a8-a965-4351d590b7ed/small/mnm-logo-tm-jpg-jpg.JPG https://www.yemenhealthreport.com/article/903363417-paul-markovich-discusses-healthcare-reform-through-the-worthy-movement-on-yourupdatetv Yemen Health Report en PressRelease 2026-04-02T14:12:48+00:00 Paul Markovich Discusses Healthcare Reform Through the Worthy Movement on YourUpdateTV https://ml.globenewswire.com/media/5115f449-412d-4a05-bbcb-add09b3f2838/small/blank-logo-png.png https://www.yemenhealthreport.com/article/903362971-biocardia-files-request-for-meeting-with-fda-to-discuss-accelerated-approval-pathway-for-cardiamp-system-in-ischemic-heart-failure Yemen Health Report en PressRelease 2026-04-02T14:11:34+00:00 BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure https://ml.globenewswire.com/media/4641bb53-4913-4654-a337-79383a5c7ab9/small/biocardia-final-logo-2016-jpeg-jpg.jpg https://www.yemenhealthreport.com/article/903362873-visory-health-ranks-among-top-u-s-prescription-cards-providing-millions-of-americans-access-to-affordable-medications Yemen Health Report en PressRelease 2026-04-02T14:11:09+00:00 Visory Health Ranks Among Top U.S. Prescription Cards Providing Millions of Americans Access to Affordable Medications https://ml.globenewswire.com/media/e5a74903-3e24-4101-9d07-c377482b32ec/small/visory-health-logo-png.png https://www.yemenhealthreport.com/article/903362348-curonix-llc-announces-expanded-reimbursement-coverage-for-freedom-peripheral-nerve-stimulator-pns-system-providing-access-to-an-additional-27 Yemen Health Report en PressRelease 2026-04-02T14:00:00+00:00 Curonix LLC Announces Expanded Reimbursement Coverage for Freedom® Peripheral Nerve Stimulator (PNS) System, Providing Access To An Additional 27 Million Covered Lives Nationwide https://ml.globenewswire.com/media/6eea76ae-3d4d-421b-886f-9e9da10f08bf/small/curonix-primarylogo-cmyk-png.png https://www.yemenhealthreport.com/article/903362591-geneproof-announces-cmv-ivdr-launch-on-the-mycrobe-fully-automated-system-for-transplant-care Yemen Health Report en PressRelease 2026-04-02T13:59:06+00:00 GeneProof Announces CMV IVDR Launch on the myCROBE™ Fully Automated System for Transplant Care https://ml.globenewswire.com/media/MDJlNGYyYTgtNjZhNC00MmIxLTgwYmQtNzVjMDg5MDk1MTM3LTUwMDE2MDU3Mi0yMDI2LTA0LTAyLWVu/tiny/GeneProof-part-of-NuvinkaDX.png https://www.yemenhealthreport.com/article/903362218-mimedx-to-sponsor-leading-advanced-wound-care-conferences Yemen Health Report en PressRelease 2026-04-02T13:15:00+00:00 MIMEDX to Sponsor Leading Advanced Wound Care Conferences https://ml.globenewswire.com/media/2a60ab36-4917-479c-b53a-4f2113ca347d/small/mimedx-png.png https://www.yemenhealthreport.com/article/903344419-global-flexible-pcb-market-to-nearly-double-reaching-41-7-billion-by-2030-on-surging-demand-from-consumer-electronics-evs-and-5g-infrastructure Yemen Health Report en PressRelease 2026-04-02T13:06:30+00:00 Global Flexible PCB Market to Nearly Double, Reaching $41.7 Billion by 2030 on Surging Demand from Consumer Electronics, EVs and 5G Infrastructure https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.yemenhealthreport.com/article/903343209-from-lab-fiber-to-luxury-fabric-kraig-biocraft-laboratories-targets-apparel-first-with-engineered-spider-silk Yemen Health Report en PressRelease 2026-04-02T13:05:00+00:00 From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets Apparel First with Engineered Spider Silk https://ml.globenewswire.com/media/ZWEyZTUxNjctYmYxZS00MzM1LWI4ODYtZDFiMjc0ZjU5YTY5LTUwMDE1MTA3NC0yMDI2LTA0LTAyLWVu/tiny/24-7-Market-News-and-Kraig-Lab.png https://www.yemenhealthreport.com/article/903343771-sienna-announces-first-quarter-2026-results-release-date-and-conference-call Yemen Health Report en PressRelease 2026-04-02T13:00:00+00:00 Sienna Announces First Quarter 2026 Results Release Date and Conference Call https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.yemenhealthreport.com/article/903343778-prenetics-announces-nba-champion-and-two-time-mvp-giannis-antetokounmpo-as-im8-global-partner-and-shareholder-in-multi-year-partnership Yemen Health Report en PressRelease 2026-04-02T13:00:00+00:00 Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership https://ml.globenewswire.com/media/bc89f070-b05a-450e-8fbe-c22e860740da/medium/giannis-im8.jpg https://www.yemenhealthreport.com/article/903341669-protecting-healthy-futures-unity-consortium-urges-families-to-prioritize-adolescent-health-during-immunization-action-week Yemen Health Report en PressRelease 2026-04-02T12:55:00+00:00 Protecting Healthy Futures: Unity Consortium Urges Families to Prioritize Adolescent Health During Immunization Action Week https://ml.globenewswire.com/media/2b3eeef1-5425-448e-bb1f-18115321d7a8/small/unity-logo-horiz-png.png https://www.yemenhealthreport.com/article/903341881-dr-joseph-mikhael-steps-into-new-role-as-medical-advisor-for-the-international-myeloma-foundation Yemen Health Report en PressRelease 2026-04-02T12:45:00+00:00 Dr. Joseph Mikhael Steps into New Role as Medical Advisor for the International Myeloma Foundation https://ml.globenewswire.com/media/f70068f9-568b-4858-8283-3c96a2db91d6/small/imf-logo-png.png https://www.yemenhealthreport.com/article/903343796-entera-bio-announces-pricing-of-10-0-million-direct-investment-by-bvf-partners-with-potential-for-up-to-24-5-million-in-total-proceeds Yemen Health Report en PressRelease 2026-04-02T12:45:00+00:00 Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds https://ml.globenewswire.com/media/9b4ae2bf-733d-4180-b48c-d0fa3f26c81a/small/logo-png.png https://www.yemenhealthreport.com/article/903344079-catalyst-medtech-announces-acquisition-of-x3d Yemen Health Report en PressRelease 2026-04-02T12:39:45+00:00 Catalyst MedTech Announces Acquisition of X3D https://ml.globenewswire.com/media/NTczOTM3ZWYtMGI1YS00ZTAyLWE5NGEtN2ZkZmI1MTFmZjhjLTEzMTYxMTAtMjAyNi0wNC0wMi1lbg==/tiny/Catalyst-MedTech.png https://www.yemenhealthreport.com/article/903344092-practicelink-reveals-evolved-brand-identity-focused-on-clarity-simplicity-and-trust-for-healthcare-providers-and-recruiters Yemen Health Report en PressRelease 2026-04-02T12:34:44+00:00 PracticeLink Reveals Evolved Brand Identity Focused on Clarity, Simplicity and Trust for Healthcare Providers and Recruiters https://ml.globenewswire.com/media/4489702d-d167-45a5-8e6b-873bd89d1590/small/2026-practicelink-logo-vertical-clr-png.png https://www.yemenhealthreport.com/article/903341101-biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-trial-supplies Yemen Health Report en PressRelease 2026-04-02T12:30:00+00:00 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies https://ml-eu.globenewswire.com/media/8367259c-e117-4264-9988-26f7e36b032f/small/biodexa-logo-square-1-png.png https://www.yemenhealthreport.com/article/903341980-intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510-k-clinical-program-targeting-multi-billion-dollar-u-s-drug-screening Yemen Health Report en PressRelease 2026-04-02T12:30:00+00:00 Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market https://ml.globenewswire.com/media/d4eaef42-9420-48b7-8019-0285720d678c/small/ibs-primary-logo-blue-png.png https://www.yemenhealthreport.com/article/903342712-ultragenyx-announces-u-s-fda-acceptance-of-bla-resubmission-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a-mps-iiia Yemen Health Report en PressRelease 2026-04-02T12:30:00+00:00 Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) https://ml.globenewswire.com/media/121a9bda-7a64-41f8-85e8-1693a2dfa977/small/ultragenyx-cmyk-png.png https://www.yemenhealthreport.com/article/903342973-abeona-therapeutics-announces-new-qualified-treatment-center-for-zevaskyn-in-new-york Yemen Health Report en PressRelease 2026-04-02T12:30:00+00:00 Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://www.yemenhealthreport.com/article/903343218-onconetix-highlights-realbotix-ai-humanoid-robot-delivery-update Yemen Health Report en PressRelease 2026-04-02T12:30:00+00:00 Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update https://ml.globenewswire.com/media/4824d51d-2ecb-4f49-8b75-fe9b920e7b1c/small/onconetix-logo-jpg.jpg https://www.yemenhealthreport.com/article/903343227-oncotelic-therapeutics-announces-strategic-partnership-with-techforce-robotics-to-commercialize-pdaoai-enhanced-gmp-robotics-platform Yemen Health Report en PressRelease 2026-04-02T12:30:00+00:00 Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform https://ml.globenewswire.com/media/aa650511-a1c3-496e-803a-448d7f8d409a/small/picture1-jpg.jpg https://www.yemenhealthreport.com/article/903343744-sienna-completes-acquisition-in-greater-toronto-area Yemen Health Report en PressRelease 2026-04-02T12:30:00+00:00 Sienna Completes Acquisition in Greater Toronto Area https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.yemenhealthreport.com/article/903341404-nanox-signs-distribution-agreement-with-integrity-medical-service-inc-to-deploy-nanox-arc-systems Yemen Health Report en PressRelease 2026-04-02T12:11:00+00:00 Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems https://ml-eu.globenewswire.com/media/7a1764f8-84e3-4b28-ae23-9add5d57c378/small/nanox-logo-4-png.png https://www.yemenhealthreport.com/article/903342205-curanex-expands-its-drug-development-pipeline-to-include-cancer-cachexia-representing-a-multi-billion-dollar-market-opportunity-and-important-step-in Yemen Health Report en PressRelease 2026-04-02T12:07:00+00:00 Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company https://ml.globenewswire.com/media/29bc3de5-6a82-4a17-a165-6a79eef16d74/small/logo-png.png https://www.yemenhealthreport.com/article/903341085-mdic-appoints-philips-chief-medical-officer-carla-goulart-peron-as-new-board-member Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member https://ml-eu.globenewswire.com/media/e5826782-01bc-45e7-b448-9ca1eae0125e/small/philips-logo-logotype-emblem-700x128-png.png https://www.yemenhealthreport.com/article/903341734-picard-medical-syncardia-coo-to-deliver-keynote-at-venture-caf-phoenix-during-arizona-tech-week Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week https://ml.globenewswire.com/media/93c733bb-b54a-41af-856b-6d01c1f724a2/small/syncardia-x-picard-email-signature-2025-1-png.png https://www.yemenhealthreport.com/article/903341755-tvardi-therapeutics-to-participate-in-the-raymond-james-biotech-innovation-symposium Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium https://ml.globenewswire.com/media/65859e40-e7db-474e-b604-78033b160f6b/small/tvardi-therapeutics-logo-1200-jpg.jpg https://www.yemenhealthreport.com/article/903341946-catheter-precision-engages-strategic-advisor Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Catheter Precision Engages Strategic Advisor https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.yemenhealthreport.com/article/903341989-calidi-biotherapeutics-to-present-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meeting-in-april-2026 Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://www.yemenhealthreport.com/article/903342225-emergent-biosolutions-participates-in-upcoming-international-preparedness-conferences Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Emergent BioSolutions Participates in Upcoming International Preparedness Conferences https://ml.globenewswire.com/media/56a9097d-af91-4bcf-8c42-5905e1614ef1/small/emerge-png.png https://www.yemenhealthreport.com/article/903342277-cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-infection-treatment-and-preventive Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive https://ml.globenewswire.com/media/a5071a3a-c592-43ba-bfee-77c2867982ba/small/cocrystal-logo-final-highres-792x612-png.png https://www.yemenhealthreport.com/article/903342676-milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/49b2e16b-2deb-4c9e-9c20-6cc4fd6c15ab/small/milestone-pharmaceuticals-logo-png.png https://www.yemenhealthreport.com/article/903343297-bionano-announces-publication-from-johns-hopkins-and-md-anderson-showing-that-ogm-can-outperform-traditional-methods-in-analysis-of-multiple-myeloma Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma https://ml.globenewswire.com/media/5ba4072e-6e59-46e7-847c-6aaf7755bbbf/small/bionano-rgb-png.png https://www.yemenhealthreport.com/article/903343298-revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer  https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.yemenhealthreport.com/article/903343584-commure-introduces-dictation-ai-powered-clinical-voice-now-at-the-cursor Yemen Health Report en PressRelease 2026-04-02T12:00:00+00:00 Commure Introduces Dictation: AI-Powered Clinical Voice, Now at the Cursor https://ml.globenewswire.com/media/1136e76f-ef70-46bf-997e-5f9b1b8b2ff6/small/commure-logo-full-horizontal-black-3-png.png https://www.yemenhealthreport.com/article/903341778-plus-therapeutics-secures-highmark-coverage-for-cnside-csf-assay-expanding-reimbursement-to-75-million-covered-lives Yemen Health Report en PressRelease 2026-04-02T11:30:00+00:00 Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://www.yemenhealthreport.com/article/903341792-mink-therapeutics-to-present-new-data-at-asgct-2026-highlighting-context-dependent-activity-of-inkt-cell-therapy Yemen Health Report en PressRelease 2026-04-02T11:30:00+00:00 MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy https://ml.globenewswire.com/media/6aa8e960-515a-40d6-9894-39ca47f5c84e/small/mink-logo-loyal-blue-and-light-blue-png.png https://www.yemenhealthreport.com/article/903342388-context-therapeutics-announces-ctim-76-receives-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer Yemen Health Report en PressRelease 2026-04-02T11:30:00+00:00 Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer https://ml.globenewswire.com/media/67b45666-397e-4c48-af45-ffd653bbfddf/small/context-therapeutics-inc.jpg https://www.yemenhealthreport.com/article/903342707-annovis-secures-u-s-patent-for-buntanetap-in-the-prevention-and-treatment-of-neurological-injuries-caused-by-brain-infections Yemen Health Report en PressRelease 2026-04-02T11:30:00+00:00 Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections https://ml.globenewswire.com/media/7ee459df-d33f-4f42-b27c-3bd20487d50c/small/annovis-corp-image-png.png https://www.yemenhealthreport.com/article/903342662-cylinder-health-launches-stool-scan-to-innovate-and-standardize-one-of-gi-care-s-most-subjective-signals Yemen Health Report en PressRelease 2026-04-02T11:10:00+00:00 Cylinder Health launches Stool Scan to innovate and standardize one of GI care’s most subjective signals https://ml.globenewswire.com/media/cfb89636-f442-479b-87c5-e2c3f43b777c/small/main-cylinder-wordmark-rgb-black-png.png https://www.yemenhealthreport.com/article/903343341-adagene-announces-pricing-of-us-70-0-million-public-offering-of-adss Yemen Health Report en PressRelease 2026-04-02T11:10:00+00:00 Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://www.yemenhealthreport.com/article/903342592-cartesian-therapeutics-announces-new-employment-inducement-grants Yemen Health Report en PressRelease 2026-04-02T11:05:00+00:00 Cartesian Therapeutics Announces New Employment Inducement Grants https://ml.globenewswire.com/media/2bf78841-be30-4bb5-bfb5-0b5f383f3302/small/cartesian-logo-color-png.png https://www.yemenhealthreport.com/article/903343176-adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-adg126-in-combination-with-incyte-s-tgf-r2xpd-1-bispecific-antibody Yemen Health Report en PressRelease 2026-04-02T11:01:00+00:00 Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://www.yemenhealthreport.com/article/903342811-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-late-line-patients-with-microsatellite-stable Yemen Health Report en PressRelease 2026-04-02T11:00:00+00:00 Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://www.yemenhealthreport.com/article/903342871-neutrolis-announces-positive-first-in-human-phase-1a-results-from-liberate-i-trial-of-ntr-1011-a-first-in-class-dnase1l3-fusion-protein Yemen Health Report en PressRelease 2026-04-02T11:00:00+00:00 Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein https://ml.globenewswire.com/media/44cdba09-fdb9-4ee1-b7bf-1dcfe5784800/small/20180228-opr-or-logos-biz-wd-neutrolis-logo-1-jpg.jpg https://www.yemenhealthreport.com/article/903343172-skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1 Yemen Health Report en PressRelease 2026-04-02T11:00:00+00:00 Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development https://ml.globenewswire.com/media/905e06d8-af43-4f7a-b097-8c12ce1d3aa0/small/skye-darkblue-jpg.jpg https://www.yemenhealthreport.com/article/903321591-pharvaris-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update Yemen Health Report en PressRelease 2026-04-02T10:50:00+00:00 Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png https://www.yemenhealthreport.com/article/903321923-burning-rock-announces-founder-s-purchase-of-its-adss Yemen Health Report en PressRelease 2026-04-02T10:25:59+00:00 Burning Rock Announces Founder’s Purchase of Its ADSs https://ml.globenewswire.com/media/904d8c1b-eae2-4b6f-83ed-3cb8d0ad31f6/small/logo-01-png.png https://www.yemenhealthreport.com/article/903321555-arch-biopartners-closes-non-brokered-private-placement Yemen Health Report en PressRelease 2026-04-02T09:45:00+00:00 Arch Biopartners Closes Non-Brokered Private Placement https://ml.globenewswire.com/media/8fae7e83-0899-4bbc-ba40-0250cdb9aea7/small/logo-png.png https://www.yemenhealthreport.com/article/903321482-roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b-3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for Yemen Health Report en PressRelease 2026-04-02T09:00:00+00:00 Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) https://ml.globenewswire.com/media/f1a5db68-ee4f-437f-b4e6-2b840ae6a536/small/roivantlogo-png.png https://www.yemenhealthreport.com/article/903321557-priovant-expands-brepocitinib-development-program-with-new-phase-2b-3-trial-in-lichen-planopilaris-lpp Yemen Health Report en PressRelease 2026-04-02T09:00:00+00:00 Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) https://ml.globenewswire.com/media/OTFhNWNlNjItZDZhZC00NWMwLTg1ZDEtMDE5MGI1ODhhYjZjLTEwMzAxODQtMjAyNi0wNC0wMi1lbg==/tiny/Roivant-Sciences-Inc-.png https://www.yemenhealthreport.com/article/903321596-immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted Yemen Health Report en PressRelease 2026-04-02T09:00:00+00:00 Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) https://ml.globenewswire.com/media/7062c765-82cc-4ba2-ba1f-4b1396b9b052/small/immulogo-jpg.jpg https://www.yemenhealthreport.com/article/903303851-mygevity-announces-nationwide-launch-of-integrated-health-data-platform Yemen Health Report en PressRelease 2026-04-02T08:31:46+00:00 MyGevity Announces Nationwide Launch of Integrated Health Data Platform https://ml.globenewswire.com/Resource/Download/57c484c8-5351-4c6a-9b57-34085204291c/image1.png https://www.yemenhealthreport.com/article/903247534-celldex-announces-pricing-of-300-million-public-offering-of-common-stock Yemen Health Report en PressRelease 2026-04-02T01:48:19+00:00 Celldex Announces Pricing of $300 Million Public Offering of Common Stock https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://www.yemenhealthreport.com/article/903247472-metatrim-bhb-claims-evaluated-the-quick-burn-keto-bhb-formula-everyone-is-researching-meta-trim-ketones Yemen Health Report en PressRelease 2026-04-02T01:34:30+00:00 MetaTrim BHB Claims Evaluated: The Quick Burn Keto BHB Formula Everyone is Researching, Meta Trim Ketones https://zingfast.com/wp-content/uploads/2026/04/MetaTrim-BHB.jpg https://www.yemenhealthreport.com/article/903247452-good-oral-health-isn-t-complicated-alberta-s-dentists-want-you-to-know-what-works Yemen Health Report en PressRelease 2026-04-02T01:10:54+00:00 Good oral health isn't complicated — Alberta's dentists want you to know what works https://ml.globenewswire.com/media/caec844b-ce06-4a8a-8b80-a9cc1fb1337e/small/ada-rgb-colour-highres-png.png https://www.yemenhealthreport.com/article/903230162-telix-appoints-david-gill-as-non-executive-director Yemen Health Report en PressRelease 2026-04-01T23:53:07+00:00 Telix Appoints David Gill as Non-Executive Director https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.yemenhealthreport.com/article/903215210-beam-therapeutics-announces-publication-of-beacon-phase-1-2-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal Yemen Health Report en PressRelease 2026-04-01T21:12:19+00:00 Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine https://ml.globenewswire.com/media/03af3276-c254-436a-b40d-2ad9a1025f95/small/beamlogo-color-cmyk-jpg.jpg https://www.yemenhealthreport.com/article/903213980-adagene-reports-full-year-2025-financial-results-and-provides-corporate-update Yemen Health Report en PressRelease 2026-04-01T21:00:00+00:00 Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://www.yemenhealthreport.com/article/903214873-zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-01T21:00:00+00:00 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/1b481d6d-51c9-44f0-b33f-81feb1061d2e/small/zentalis-logo-png.png https://www.yemenhealthreport.com/article/903215040-vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Yemen Health Report en PressRelease 2026-04-01T21:00:00+00:00 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/dde67700-b1b4-40c4-b930-13bd71804762/small/vor-wordmark-rgb-fullcolor-070920-png.png https://www.yemenhealthreport.com/article/903214932-pennant-acquires-arbor-rose-senior-living-community-in-mesa-arizona Yemen Health Report en PressRelease 2026-04-01T20:53:32+00:00 Pennant Acquires Arbor Rose Senior Living Community in Mesa, Arizona https://ml.globenewswire.com/media/d50f543c-fc54-437d-8007-600644587dfe/small/pennant-logo-png.png https://www.yemenhealthreport.com/article/903215016-herz-p1-brand-under-investigation-review-the-herz-smart-ring-p1-smart-band-smart-p1-body-scale-product-details Yemen Health Report en PressRelease 2026-04-01T20:38:44+00:00 Herz P1 Brand Under Investigation: Review the Herz Smart Ring, P1 Smart Band & Smart P1 Body Scale Product Details https://zingfast.com/wp-content/uploads/2026/04/Herz-P1-Brand-Review.jpg https://www.yemenhealthreport.com/article/903196369-abivax-publishes-financial-reports-with-the-french-and-u-s-securities-regulatory-agencies Yemen Health Report en PressRelease 2026-04-01T20:05:00+00:00 Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.yemenhealthreport.com/article/903196587-sight-sciences-interventional-technologies-for-glaucoma-and-dry-eye-disease-to-be-featured-in-multiple-clinical-presentations-at-the-2026-american Yemen Health Report en PressRelease 2026-04-01T20:05:00+00:00 Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting https://ml.globenewswire.com/media/e7536623-9fa4-42d0-896d-04ddb984ef4e/small/sght-logo-png.png https://www.yemenhealthreport.com/article/903196986-resmed-to-report-third-quarter-fiscal-2026-earnings-on-april-30-2026 Yemen Health Report en PressRelease 2026-04-01T20:05:00+00:00 Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026 https://ml.globenewswire.com/media/fb7a34f4-d074-4bcf-b827-7a6a60924c46/small/resmed-h-pos-clr-rgb-250121-png.png https://www.yemenhealthreport.com/article/903197143-akebia-therapeutics-appoints-biopharmaceutical-leader-philip-vickers-ph-d-to-its-board-of-directors Yemen Health Report en PressRelease 2026-04-01T20:05:00+00:00 Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.yemenhealthreport.com/article/903196814-carlsmed-inc-to-participate-in-the-25th-annual-needham-virtual-conference Yemen Health Report en PressRelease 2026-04-01T20:01:00+00:00 Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference https://ml.globenewswire.com/media/ee16eff2-e0d6-40ca-95c5-4dd84bb4cc5f/small/carlsmed-png.png https://www.yemenhealthreport.com/article/903197587-celldex-announces-proposed-public-offering-of-common-stock Yemen Health Report en PressRelease 2026-04-01T20:01:00+00:00 Celldex Announces Proposed Public Offering of Common Stock https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://www.yemenhealthreport.com/article/903197786-berberine-weight-loss-patches-by-purisaki-under-investigation-urgent-warning-issued Yemen Health Report en PressRelease 2026-04-01T19:52:45+00:00 Berberine Weight Loss Patches by Purisaki Under Investigation (URGENT Warning Issued) https://zingfast.com/wp-content/uploads/2026/04/Berberine-Weight-Loss-Patches-by-Purisaki.jpg https://www.yemenhealthreport.com/article/903181712-renovorx-named-to-fast-company-s-annual-list-of-the-world-s-most-innovative-companies-of-2026 Yemen Health Report en PressRelease 2026-04-01T18:20:16+00:00 RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 https://ml.globenewswire.com/media/e18bf823-ff44-4bbd-82b9-3a311d58dad8/small/final-logo-horizontal-png.png https://www.yemenhealthreport.com/article/903181579-cloud-computing-in-cell-biology-genomics-and-drug-development-to-reach-15-6-billion-by-2030-as-biological-data-explosion-drives-demand Yemen Health Report en PressRelease 2026-04-01T17:47:07+00:00 Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.yemenhealthreport.com/article/903181152-xortx-confirms-effective-date-of-share-consolidation Yemen Health Report en PressRelease 2026-04-01T17:00:00+00:00 XORTX Confirms Effective Date of Share Consolidation https://ml.globenewswire.com/media/9898c4f8-b373-438a-abfa-709c4372a061/small/xortx-logo-jpg.jpg https://www.yemenhealthreport.com/article/903165731-chemed-to-report-first-quarter-2026-earnings-april-23-related-conference-call-to-be-held-on-april-24 Yemen Health Report en PressRelease 2026-04-01T16:00:00+00:00 Chemed To Report First Quarter 2026 Earnings April 23, Related Conference Call To Be Held On April 24 https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://www.yemenhealthreport.com/article/903166771-diagnos-successfully-completes-the-renewal-of-us-fda-medical-device-establishment-registration Yemen Health Report en PressRelease 2026-04-01T15:50:37+00:00 DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration https://ml.globenewswire.com/media/aaea38c5-db20-4091-bd36-338d3bb064d1/small/diagnos-logo-en-transparent-png.png https://www.yemenhealthreport.com/article/903166885-diagnos-compl-te-avec-succ-s-le-processus-de-renouvellement-d-enregistrement-d-tablissement-aupr-s-de-la-us-fda Yemen Health Report en PressRelease 2026-04-01T15:50:37+00:00 DIAGNOS complète avec succès le processus de renouvellement d’enregistrement d’établissement auprès de la US-FDA https://ml.globenewswire.com/media/2ce926bc-c255-4b04-b9f7-739933c01051/small/diagnos-systemes-medicaux-logo-fr.png https://www.yemenhealthreport.com/article/903166501-global-virus-network-launches-expanded-global-guardians-for-pandemic-preparedness-program-for-florida-high-school-students Yemen Health Report en PressRelease 2026-04-01T15:42:00+00:00 Global Virus Network Launches Expanded “Global Guardians for Pandemic Preparedness” Program for Florida High School Students https://ml.globenewswire.com/media/6c1b2724-7b9b-469a-a7c3-bc0a64d716ae/small/gvn-lt-gr-gradiant-jpg.jpg